---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-022421"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2023-06-16T23:59:59+00:00"
generated_at: "2026-06-13T22:29:05.431331+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Aadi Bioscience annual meeting elects directors, says-on-pay passes, auditor ratified

## Summary
- Elected three Class III directors: Aghazadeh (8.36M for), Maroun (9.87M), Reeve (9.87M).
- Advisory say-on-pay approved: 9.74M for, 0.28M against, 17K abstentions.
- Shareholders voted for annual say-on-pay frequency (9.83M for 1 year); next vote by 2029.
- Ratified BDO USA as auditor for FY2023: 13.85M for, 73K against, 3K abstentions.

## SEC filing metadata
- accession: 0001628280-23-022421
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2023-06-16T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000162828023022421/0001628280-23-022421-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000162828023022421/aadi-20230614.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-022421
- JSON: https://secwatch.observer/filing/0001628280-23-022421.json
- Plain text: https://secwatch.observer/filing/0001628280-23-022421.txt

## Key facts
- Shareholder Votes
  Whitehawk Therapeutics, Inc. shareholders approved Ratification of the appointment of BDO USA LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-14 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-14
  source text: For Against Abstentions 13,850,448 72,970 2,786
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000162828023022421/0001628280-23-022421-index.htm
- Shareholder Votes
  Whitehawk Therapeutics, Inc. shareholders approved To approve, on an advisory (non-binding) basis, the frequency of future Say-on-Pay Votes. at the 2023-06-14 meeting.
  - Proposal: say on pay frequency
  - Outcome: passed
  - Meeting: 2023-06-14
  source text: 1 Year 2 Years 3 Years Abstentions Broker Non-Votes 9,832,520 2,546 75,231 120,267 N/A
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000162828023022421/0001628280-23-022421-index.htm
- Shareholder Votes
  Whitehawk Therapeutics, Inc. shareholders approved To approve, on an advisory basis, the compensation of the named executive officers identified in the 2022 Summary Compensation Table in the “Executive Compensation” section of the Proxy Statement. at the 2023-06-14 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-14
  source text: For Against Abstentions Broker Non-Votes 9,738,074 275,337 17,153 3,895,640
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000162828023022421/0001628280-23-022421-index.htm
- Shareholder Votes
  Whitehawk Therapeutics, Inc. shareholders approved Election of three Class III directors to serve until the 2026 Annual Meeting of Stockholders and until their respective successors have been elected or qualified. at the 2023-06-14 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-14
  source text: Broker Director For Withheld Non-Votes Behzad Aghazadeh, Ph.D. 8,361,137 1,669,427 3,895,640 Richard Maroun 9,872,401 158,163 3,895,640 Emma Reeve 9,871,998 158,566 3,895,640
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000162828023022421/0001628280-23-022421-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.